Effects of combination of pargyline and doxorubicin on proliferation and migration of tripple negative breast cancer 4T-1 cells
10.3969/j.issn.1001-1978.2021.04.022
- Author:
Xue REN
1
;
Shi-En WANG
1
;
Xiang WANG
1
;
Qian-Ying CHEN
1
;
Hao ZHANG
1
;
Heng-Xing TAN
1
;
Chun-Yu CAO
1
;
Shi-En WANG
2
;
Yan XIA
3
Author Information
1. Hubei Key Lab of Tumor Microenvironment and Immunotherapy, China Three Gorges University
2. The Second People's Hospital of Wuwei
3. Hubei Provincial Key Lab of Occurrence and Intervention of Rheumatic Diseases, The Affiliated Hospital of Hubei University for Nationalities
- Publication Type:Journal Article
- Keywords:
4T-1 cells;
combination medication;
doxorubicin;
epithelial mesenchymal transition;
pargyline;
tripple negative breast cancer
- From:
Chinese Pharmacological Bulletin
2021;37(4):571-578
- CountryChina
- Language:Chinese
-
Abstract:
Aim To study the combination of lysinespecifc demethylase 1 (lysine-specifc demethylase 1, LSD1) inhibitor pargyline and the chemotherapy drug doxorubicin on the proliferation, migration and invasion of murine triple negative breast cancer 4T-1 cells. Methods In vitro, the effect on the proliferation, invasion and migration of 4T-1 cells of the combination of these two drugs were detected with CCK-8 method, lactate dehydrogenase release test, Chou-Talay method, Scratch test, Transwell assay, Western blot and etc. Tumor-bearing mice were used to investigate the combined effect of these two drugs on the proliferation of 4T-1 cells in vivo. Results The combination of pargyline and doxorubicin effectively inhibited the proliferation, migration and invasion of 4T-1 cells. Compared with single drug group, the combination of these two drugs could significantly inhibit the proliferation of breast cancer and prolong the survival time of mice with triple negative breast cancer. Conclusions The combined application of pargyline and doxorubicin has a synergistic inhibitory effect on the proliferation, migration and invasion of mouse breast cancer 4T-1 cells, and has potential value for clinical treatment on triplenegative breast cancer.
